Corcept Therapeutics (NasdaqCM:CORT) saw a remarkable 36% increase in its share price in the last quarter, driven by several key developments. The company's significant announcement on March 31 ...

The superlative Gold Series welcomes the A-10 Cocobolo, a high-end grand auditorium cutaway that is all kinds of fancy ...

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...

Corcept Therapeutics Incorporated’s CORT share price has dipped by 7.02%, which has investors questioning if this is right ...

CORT's NDA for Relacorilant in Cushing’s Syndrome Relacorilant is Corcept’s lead candidate, which is being developed for treating patients with Cushing’s syndrome. In December 2024 ...

It has been about a month since the last earnings report for Corcept Therapeutics (CORT). Shares have lost about 5.3% in that time frame, underperforming the S&P 500. Will the recent negative ...